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ABSTRACT
Objectives: The aim of this study was to assess the treatment options and survival of uterine cervical cancer (UCC) patients 
who develop isolated pulmonary metastases (IPM) and to establish risk factors for IPM. 
Material and Methods: Data from patients diagnosed with UCC between June 1991 and January 2017 at the Gynecological 
Oncology Department, Tepecik Training and Research Hospital, were investigated. In total, 43 cases with IPM were evalu-
ated retrospectively. Additionally, 172 control patients diagnosed with UCC without recurrence were matched according 
to the International Federation of Gynecology and Obstetrics (FIGO) 2009 stage when the tumor was diagnosed. They were 
selected using a dependent random sampling method. 
Results: Of the 890 patients with UCC, 43 (4.8%) had IPM. The presence of lymphovascular space invasion (LVSI) and 
a mid-corpuscular volume (MCV) < 80 fL were statistically significant prognostic factors for IPM development in UCC patients 
according to univariate regression analyses, and the presence of LVSI, a hemoglobin level < 12 g/dL, and an MCV < 80 fL 
were statistically significant according to the multivariate regression analyses. We were unable to assess the role of lymph 
node status (involvement or reactive) as a prognostic factor in the development of IPM, because only seven patients (16.2%) 
in the case group underwent lymph node dissection. 
Conclusions: IPM typically develops within the first 3 years after the diagnosis of UCC, and survival is generally poor. An 
MCV < 80 fL and the presence of LVSI are significant risk factors for IPM development.
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INTRODUCTION
Uterine cervical cancer (UCC) is the third-most common 
malignancy among gynecological cancers [1]. As a result 
of screening programs, the detection of early stage UCC 
has been gradually increasing. Although metastasis at the 
time of initial diagnosis of UCC is rare, 15–61% of patients 
eventually develop metastases within 28 years [2]. 
Hematogenous spread of UCC is rare; lung (36.3%), bone 
(16.3%), liver, and brain metastases are most common [3]. The 
incidence of isolated pulmonary metastasis (IPM) in UCC pa-
tients is 3.1–9.9% [3–5]. The primary cancer types that most fre-
quently cause IPM are breast, larynx, prostate, thyroid, bladder, 
stomach, and pancreatic cancers, in that order [5, 6]. Among the 
types of gynecological malignancies, sarcomas have a higher 
incidence of IPM than do epithelial cancers [6]. IPM is asympto-
matic and can be recognized by follow-up imaging methods or 
by symptoms such as cough, chest pain, hemoptysis, respira-
tory distress, and drowsiness, depending on location and size.
The mean survival of patients with metastatic UCC is 
8–13 months, and the 5-year survival rate is 7.5–16.5% [3]. 
Conventional treatments such as surgery, chemotherapy 
(CT), and radiotherapy (RT) are used in early and locally 
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advanced UCC patients; however, there is no standard treat-
ment for patients with UCC with IPM. The aim of this study 
was to assess the treatment options and survival of UCC pa-
tients who develop IPM and to establish risk factors for IPM.
PATIENTS AND METHODS
Data from patients diagnosed with UCC between June 
1991 and January 2017 at the Gynecological Oncology De-
partment, Tepecik Training and Research Hospital, were 
investigated. In total, 43 cases with IPM were evaluated 
retrospectively. Additionally, 172 control patients diagnosed 
with UCC without recurrence were matched according to 
the International Federation of Gynecology and Obstetrics 
(FIGO) 2009 stage when the tumor was diagnosed. They 
were selected using a dependent random sampling method. 
This study was approved by the institutional ethics com-
mittee and was conducted in accordance with the ethical 
standards of the Declaration of Helsinki.
All surgical specimens were examined and interpreted 
by gynecological pathologists. Architectural grading was 
defined by standard FIGO criteria. All tumors were staged 
according to the 2009 FIGO staging system. In patients 
treated before 2009, stage was determined retrospectively 
based on surgical and pathological assessments.
Blood counts were measured at the time of the initial 
UCC diagnosis. Staging was performed according to the 
FIGO 2009 clinical staging system by examination under 
general anesthesia, and patients were evaluated using im-
aging modalities. Women completed follow-up evaluations 
every 3 months for the first 2 years, every 6 months for the 
next 3 years, and annually thereafter. Computed tomography 
or magnetic resonance imaging was performed annually.
Clinical and pathologic data were obtained from patient 
files and pathology reports. The diagnosis of pulmonary me-
tastasis was confirmed by histopathology or imaging. Patient 
age, menopausal status, disease-free survival (DFS), overall 
survival (OS), type of primary treatment (such as surgery, CT, 
RT, or chemoradiotherapy (CRT), recurrence, and treatment of 
recurrence were also investigated. Tumor size, lymphovascular 
space invasion (LVSI), number of pelvic and para-aortic lymph 
nodes, lymph node involvement, and size of vaginal and 
lymph node metastases were analyzed in accordance with 
the pathology reports. Patients with IPM were investigated in 
terms of treatment options (e.g., CT, RT, or CRT) and survival. 
DFS was defined as the time from the date of primary sur-
gery to detection of recurrence or the most recent observation. 
OS was defined as the time from the date of primary surgery 
to death or the most recent observation. Post-metastasis sur-
vival was defined as the time between the date of recurrence 
and the time of the last control clinic visit or death. Survival 
analysis was performed using the Kaplan-Meier method, and 
the results were compared by log-rank test. Logistic regression 
analysis was used to define the risk factors for IPM. The results 
are presented as odds ratios (OR) and 95% confidence interval 
(CI) CIs. Cox regression analysis was used to determine the 
factors affecting survival, with the results presented as hazard 
ratios. The Chi-square test and Student’s t-test for unpaired 
data were used for statistical analysis. All statistical analyses 
were performed using MedCalc software (version 14.0 for 
Windows; MedCalc Software bvba, Ostend, Belgium; https://
www.medcalc.org; 2016). A P-value < 0.05 was considered to 
indicate statistical significance.
RESULTS
Of the 890 patients with UCC, 43 (4.8%) had IPM. The 
median detection time of IPM was 24.0 months (range 
0–96 months) after UCC diagnosis. The demographic char-
acteristics of the patients in the IPM and control groups are 
shown in Table 1 and the primary therapies for both groups 
in Table 2. Of the IPMs, 18.6% were solitary, and 81.4% were 
multiple lesions. A median of 3 (range 2–5) lesions were 
detected in 35 patients with multiple lesions. Within the 
IPM group, 2.9% (9 of 304) patients were stage IB, 1.6% (1 of 
59) stage IIA, 6.0% (19 of 312) stage IIB, 3.4% (2 of 58) stage 
IIIA, 10.0% (6 of 60) stage IIIB, and 50.0% (6 of 12) stage IVB.
For IPM treatment, 35 (81.4%) patients received CT only, 
4 (9.3%) received surgery plus CT, 3 (7.0%) received RT, and 
1 (2.3%) received palliative support treatment. According to 
Table 1. Demographics of the study groups
Cases (43) Controls (172) P
Age, mean ± SD, years 58.9 ± 10.8 54.3 ± 10.5 0.012
Tumor size, mean ± SD, cm 4.5 ± 1.3 4.1 ± 1.5 0.145
Hemoglobin, mean ± SD, g/dL 11.8 ± 2.0 11.6 ± 1.8 0.560
MCV, mean ± SD 79 ± 9.8 83.2 ± 7.3 0.011
DFS, mean ± SD, months 29.5 ± 26.0 - -
OS, mean ± SD, months 55.0 ± 53.2 90.8 ± 57.3 0.001
Postmenopausal status, n [%] 34 (79.1) 116 (67.4) 0.095
Stage, n [%]
IB1
IB2
IIA
IIB
IIIA
IIIB
IVB
2 (4.7)
7 (16.3)
1 (2.3)
19 (44.2)
2 (4.7)
6 (14.0)
6 (14.0)
8 (4.7)
28 (16.3)
4 (2.3)
76 (44.2)
8 (4.7)
48 (27.9)
0
Histological type, n [%]
Squamous cell carcinoma
Adenocarcinoma
Adenosquamous cell carcinoma
34 (79.1)
8 (18.6)
1 (2.3)
148 (86.0)
20 (11.6)
4 (2.3)
0.476
LVSI, n [%] 36 (83.7) 94 (54.7) 0.001
Lymph node involvement, 
n [%] 4 (57.1) 16 (44.4) 0.538
DFS — disease-free survival; LVSI — lymphovascular space invasion; MCV 
— mid-corpuscular volume; OS — overall survival
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recurrence treatment, the mean survival time after recurrence 
was 17.8 ± 21.7 months in CT group, 100.0 ± 63.4 months in 
surgery plus CT group and 21.0 ± 23.6 months in RT group 
(p < 0.001). In surgery plus CT group, survival time after recur-
rence was 24, 72, 144 and 160 months. In RT group, survival 
time after recurrence was 4, 11 and 48 months. Two of the 
surgically treated patients (50.0%) underwent metastasecto-
my, and the other two (50.0%) underwent lobectomy. Three 
(75.0%) of the patients who underwent post-surgical CT 
received carboplatin + paclitaxel (6 cycles) and one (25.0%) 
received cisplatin + paclitaxel + ifosfamide (4 cycles). Of 
the patients who underwent CT only, 11 (31.4%) received 
carboplatin + paclitaxel (3–6 cycles), 8 (22.9%) received 
carboplatin + ifosfamide (2–6 cycles), 7 (20.0%) received 
cisplatin + ifosfamide (2–6 cycles), 4 (11.4%) received car-
boplatin + 5-fluorouracil (3–6 cycles), and 4 (11.4%) received 
carboplatin + cyclophosphamide (4–6 cycles). Patients re-
ceiving radiotherapy received 30–42 Gy doses.
After detection of IPM, the 1-, 2-, and 5-year survival rates 
were 31.3, 26.5, and 15.9%, respectively. The median sur-
vival time after metastasis detection was 12 months (range 
2–160 months). 
Risk factors for IPM were assessed by multivariate and 
univariate logistic regression analyses (Tab. 3). The presence 
of LVSI and a mid-corpuscular volume (MCV) < 80 fL were sta-
tistically significant prognostic factors for IPM development 
in UCC patients according to univariate regression analyses, 
and the presence of LVSI, a hemoglobin level < 12 g/dL, and 
an MCV < 80 fL were statistically significant according to the 
multivariate regression analyses. We were unable to assess 
the role of lymph node status (involvement or reactive) as 
a prognostic factor in the development of IPM, because 
only seven patients (16.2%) in the case group underwent 
lymph node dissection. 
The factors affecting survival after IPM in UCC are listed 
in Table 4. Postmenopausal status was a significant factor 
according to the univariate analyses, and a DFS ≥ 12 months 
was significant according to the multivariate analyses.
DISCUSSION
In this case-control study, we evaluated UCC patients 
with IPM. Risk factors were compared between the case 
and control groups. Previous studies in the literature have 
investigated pulmonary metastases [1, 4, 6–10]; however, 
Table 2. Primary therapies for the study groups
Cases (43) Controls (172) P
Primary therapy, n [%]
Concurrent chemoradiotherapy
Surgery + adjuvant chemoradiotherapy
Radiotherapy
Surgery + adjuvant radiotherapy
Chemotherapy
17 (39.5)
7 (16.3)
17 (39.5)
1 (2.3)
1 (2.3)
106 (61.6)
24 (14.0)
18 (10.5)
24 (14.0)
0 (0)
0.001
Surgery, n [%]
Type 1 hysterectomy + BSO
Type 2 hysterectomy + BSO +PPLND
Type 3 hysterectomy + BSO + PPLND
PPLND
1 (12.5)
1 (12.5)
5 (62.5)
1 (12.5)
12 (25.0)
2 (4.1)
32 (66.6)
2 (4.1)
0.580
Type of chemotherapy: CCRT, n [%]
Cisplatin
Cisplatin + 5-fluorouracil
Cisplatin + carboplatin
Cisplatin + ifosfamide + paclitaxel
Number of cycles
13 (76.4)
1 (5.8)
2 (11.6)
1 (5.8)
2–6
98 (92.5)
0 (0)
6 (5.7)
2 (1.9)
2–7
0.048
0.219
Type of chemotherapy: adjuvant CT, n [%]
Cisplatin
Cisplatin + 5-fluorouracil
Carboplatin + paclitaxel
Number of cycles
5 (71.4)
1 (14.3)
1 (14.3)
6–7
22 (91.7)
0 (0)
2 (8.3)
3–7
0.144
0.002
Primary radiotherapy
Internal radiotherapy dose range, Gy
External radiotherapy dose range, Gy
5–9
45–64.8
4–9
36–61
0.464
0.147
Adjuvant radiotherapy
Internal radiotherapy dose range, Gy
External radiotherapy dose range, Gy
5–9.25
30.6–54
5–9
45–59
0.240
0.084
BSO — bilateral salpingo-oophorectomy; CCRT — concurrent chemoradiotherapy; CT — chemotherapy; PPLND — pelvic para-aortic lymphadenectomy
596
Ginekologia Polska 2018, vol. 89, no. 11
www. journals.viamedica.pl/ginekologia_polska
to our knowledge, this is the first study to investigate risk 
factors for the development of IPM and factors affecting 
survival after IPM. 
The rate of development of pulmonary metastases in 
UCC was 4.1–6.1% [8, 9]. The rates of pulmonary metastases 
were 3.2–4.2% in stage I, 5.0–13.0% in stage II, 7.4–9.4% in 
stage III, and 20.9–57.0% in stage IV disease [4, 9]. Pulmonary 
metastasis was seen in 83.9–96.0% of patients during the first 
2 years after UCC diagnosis [9]. The mean duration of pulmo-
nary metastases was 12–13 months [1, 10]. In our study, when 
the IPM incidence was 4.8%, the mean detection time was 
24.0 months (range 1–96 months) after UCC diagnosis. Of 
the IPM patients, 79.1% had squamous cell carcinoma (SCC), 
18.6% adenocarcinoma, and 2.3% adenosquamous cancer. 
Within the IPM group, the rates of diagnosis of stage IB, stage 
IIA, stage IIIA, stage IIIB, and stage IVB were 2.9%, 1.6%, 6.0%, 
3.4%, 10.0%, and 50.0%, respectively.
Risk factors for pulmonary metastasis, which is the most 
common site of hematogenous metastasis, have been in-
vestigated in previous studies [3–5]. Those studies identi-
fied pelvic lymph node involvement, diagnosis of non-SCC, 
and tumor size > 4 cm as risk factors for the development 
of pulmonary metastases in UCC patients [9, 11]. In our 
cohort, the presence of LVSI (OR 4.6, 95% CI 1.6–13.0), a he-
moglobin level < 12 g/dL (OR 8.4, 95% CI 2.2–33.3), and 
an MCV < 80 fL (OR 21.0, 95% CI 5.3–82.4) were statistically 
significant prognostic factors, according to the multivari-
ate regression analysis. The presence of LVSI (OR 4.2, 95% 
CI 1.8–10.1) and an MCV < 80 fL (OR 3.7, 95% CI 1.7–7.6) 
were statistically significant prognostic factors according 
to univariate regression analysis for hematogenously de-
veloped IPM. Although LVSI was previously investigated 
as a risk factor for pulmonary metastasis, MCV has not 
been investigated in hematological metastasis previously; 
an MCV < 80 fL was found to be a risk factor in our study. 
Notably, menopausal status, tumor size, hydronephrosis, 
and non-SCC histological type, which have been previously 
presented as risk factors for several types of metastases, 
were not identified as statistically significant risk factors for 
IPM development in our study. 
Table 4. Assessment of prognostic factors affecting survival time after metastasis
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
LVSI 0 - 0.630 0.5 0.1–1.9 0.375
Hemoglobin (< 12 g/dL) 0.9 0.1–4.6 0.924 0.6 0.2–1.7 0.404
MCV (< 80 fL) 0.5 0.1–2.8 0.465 1.1 0.4–3.2 0.726
Postmenopausal 7.2 1.1–19.4 0.022 0.3 0.1–1.4 0.167
Tumor size (≥ 4 cm) 0.5 0.1–8.0 0.521 2.0 0.4–8.6 0.323
Hydronephrosis 0.7 0.1–5.1 0.760 0.4 0.1–2.9 0.410
Non-SCC histological type 1.0 0.1–8.2 0.984 0.6 0.2–1.8 0.444
DFS (≥ 12 months) 0 - 0.424 2.9 1.1–7.9 0.029
Number of lesions (multiple) 1.7 0.3–9.1 0.422 4.5 0.9–22.6 0.065
CI — confidence interval; DFS — disease-free survival; HR — hazard ratio; LVSI — lymphovascular space invasion; MCV — mid-corpuscular volume; SCC — squamous 
cell carcinoma
Table 3. Odds ratios from univariate and multivariate analyses using the logistic regression model, with isolated pulmonary metastasis as the 
dependent variable
Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
LVSI 4.2 1.8–10.1 0.001 4.6 1.6–13.0 0.004
Hemoglobin (< 12 g/dL) 0.7 0.3–1.4 0.341 8.4 2.2–33.3 0.002
MCV (< 80 fL) 3.7 1.7–7.6 0.001 21.0 5.3–82.4 0.001
Postmenopausal 1.8 0.8–4.0 0.141 1.6 0.5–4.6 0.359
Tumor size ( ≥ 4 cm) 1.1 0.4–2.7 0.735 1.3 0.4–4.4 0.586
Hydronephrosis 0.7 0.2–2.5 0.601 0.5 0.1–2.1 0.349
Non-SCC histological type 1.6 0.6–3.8 0.260 2.2 0.7–6.6 0.130
CI — confidence interval; LVSI — lymphovascular space invasion; OR — odds ratio; SCC — squamous cell carcinoma
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Histological type (non-SCC), age (< 60 years), solitary 
pulmonary metastasis, tumor size, presence of lymph node 
metastases, and metastatic lesions have been reported as prog-
nostic factors affecting survival after metastasis [1, 12, 13]. In 
our study, postmenopausal status (OR 7.2, 95% CI 1.1–19.4) 
was a risk factor for conditions affecting the post-recurrence 
survival time according to univariate regression analysis, and 
a DFS ≥ 12 months (OR 2.9, 95% CI 1.1–7.9) was a statistically sig-
nificant risk factor according to multivariate regression analysis. 
The median survival after lung metastasis was 18 months, 
whereas the 2- and 5-year survival rates were 37.7% and 
7.5%, respectively [3, 13]. Similarly, in our cohort, the 1-, 2-, 
and 5-year survival rates after detection of IPM were 31.3%, 
26.5%, and 15.9%, respectively. In contrast, the median sur-
vival time after metastasis detection was 12.0 months (range 
2–3160 months). The long survival time after metastasis may 
be due to isolated metastases.
Surgery combined with CT may provide a better progno-
sis for single, solitary pulmonary metastatic tumors [14]. The 
survival rate of patients with pulmonary metastasectomy 
was reported to be higher than that of patients receiving 
CT only; however, the difference was not statistically signifi-
cant [6]. Following the necessary criteria for the selection of 
cases for surgical removal of recurrent pulmonary tumors is 
recommended, with the expectation of a 30% 5-year survival 
rate [7, 9]. Survival after complete metastasectomy was 
36% at 5 years, 26% at 10 years, and 22% at 15 years (me-
dian 35 months), whereas that after incomplete resection 
was 13% at 5 years and 7% at 10 years (median 15 months) [7]. 
These outcomes indicate that metastasectomy is poten-
tially curative [7]. The following are prerequisites for the 
application of pulmonary metastasectomy: the patient is at 
low risk for surgical intervention, the primary malignancy is 
controlled or controllable, there is no evidence of metastatic 
disease elsewhere, and complete resection of pulmonary 
metastases is possible [7]. Preferred conditions include the 
absence of hilar and mediastinal lymph node metastasis, 
fewer than four pulmonary lesions, a long disease-free inter-
val, metastatic lesions no larger than 3 cm in diameter, and 
no elevation of serum tumor marker levels [7]. The response 
rate to platinum-based CT was 67.7%, with a median survival 
of 8.3 months [8]. In our study, CT was usually the only treat-
ment performed for metastasis (81.4%). For the treatment 
of metastasis, the surgical approach was performed in only 
four patients (9.4%). Experience with the surgical treatment 
of patients with IPM is lacking at our hospital. One reason for 
the low number of surgical treatments was the presence of 
multiple lesions in 81.4% of patients; another reason is that 
patients did not show a preference for surgical treatment 
when it was offered, due to the complications with surgical 
treatment and the cure rate after treatment. Accompany-
ing comorbidities (diabetes, hypertension, asthma, etc.), 
which are impediments to surgery or cause an increased 
rate of complications, with an advanced average age of 
58.9 ± 10.8 are other possible reasons. According to recur-
rence treatment, the mean survival time after recurrence 
was 17.8 ± 21.7 in CT group, 100.0 ± 63.4 in surgery plus CT 
group and 21.0 ± 23.6 months in RT group (p < 0.001). In 
surgery plus CT group, survival time after recurrence was 
24, 72, 144 and 160 months. The significant difference in 
survival times between treatment groups may be due to pa-
tients with surgery are cases with solitary lesions. Therefore, 
patients who are eligible for surgical treatment (metastasec-
tomy or lobectomy) are very fortunate in terms of survival.
The strengths of our study lie in the similarities in demo-
graphic characteristics among the study population, the avail-
ability of good follow-up data, and treatment at a single insti-
tution by the same gynecology and oncology teams. However, 
some limitations are worth mentioning. First, it was a retro-
spective analysis of UCC patients. Because of the retrospective 
nature of the study, the effects of other possible confounding 
factors, such as selection and recall bias, on our results cannot 
be ruled out. Second, although the patients in the control 
group were selected randomly to prevent bias, there were 
still differences within and between the groups with regard 
to surgery and treatment types. Third, we are aware that the 
lack of a surgery-alone treatment arm among the patients with 
recurrence is a major limitation of our study; this prevented us 
from comparing surgery with medical treatment (such as CT, 
RT, and CRT). This situation depended not only on the lack of 
surgical experience but also on patient preference. Fourth, the 
small number of patients and different treatment regimens 
used over a period of 15 years are additional limiting factors 
that may potentially affect the comparisons negatively.
In conclusion, IPM typically develops within the first 
3 years after the diagnosis of UCC, and survival is generally 
poor. An MCV < 80 fL and the presence of LVSI are signifi-
cant risk factors for IPM development. Effective treatment 
algorithms should be established to increase the survival 
of UCC patients diagnosed with IPM.
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